We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further...
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.009 | 1.18421052632 | 0.76 | 0.78 | 0.74 | 221060 | 0.75705305 | CS |
4 | -0.091 | -10.5813953488 | 0.86 | 0.8879 | 0.7341 | 290876 | 0.77811706 | CS |
12 | -0.391 | -33.7068965517 | 1.16 | 1.56 | 0.7341 | 241530 | 0.95366471 | CS |
26 | -0.191 | -19.8958333333 | 0.96 | 1.56 | 0.7341 | 180992 | 1.0239735 | CS |
52 | -0.871 | -53.1097560976 | 1.64 | 1.71 | 0.7341 | 144810 | 1.06973852 | CS |
156 | -15.731 | -95.3393939394 | 16.5 | 19.285 | 0.7341 | 208419 | 3.77973087 | CS |
260 | -25.331 | -97.0536398467 | 26.1 | 43.07 | 0.7341 | 215661 | 7.24936655 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions